P ediatric pulmonary hypertension (PH) is a complex disease associated with significant morbidity and mortality. Important pediatric PH subtypes include the following: idiopathic pulmonary arterial hypertension (IPAH), PH associated with congenital heart disease, and PH secondary to lung disease. PH-targeted medications have led to improved survival; in children who did not respond to a calcium channel blocker at heart catheterization (HC), the 4-year survival without directed pulmonary arterial hypertension therapy was poor (35%) 1 compared with a 5-year survival of 84% in children receiving PH-specific medical therapy.
P ediatric pulmonary hypertension (PH) is a complex disease associated with significant morbidity and mortality. Important pediatric PH subtypes include the following: idiopathic pulmonary arterial hypertension (IPAH), PH associated with congenital heart disease, and PH secondary to lung disease. PH-targeted medications have led to improved survival; in children who did not respond to a calcium channel blocker at heart catheterization (HC), the 4-year survival without directed pulmonary arterial hypertension therapy was poor (35%) 1 compared with a 5-year survival of 84% in children receiving PH-specific medical therapy. 2 Children with PH are considered high risk for invasive procedures and surgery, given that life-threatening complications, such as PH crisis, can occur. In PH crisis, the pulmonary vascular resistance (PVR) immediately increases to a point at which pulmonary artery pressure exceeds systemic arterial pressure, resulting in reduced pulmonary perfusion and subsequent decline in cardiac output, followed by hypoxia and biventricular failure. Common precipitants of PH crisis are as follows: infection, malfunction of pump/catheter infusing prostacyclin analog therapy, pulmonary embolism, arrhythmia, trauma, anemia, and worsening hypoxia. Hemodynamic assessment with HC is the standard tool used to evaluate hemodynamics at presentation and in reassessment after targeted therapy. 3 The overall adverse event (AE) rate with pediatric HC is relatively low at 0.1% 4 ;
however, HC in children with PH is substantially higher, with cardiac arrest occurring in 4% to 6%. 5, 6 Both single-center and pooled registry data have shown that children with PH undergoing HC have a high risk of major AEs (3.5%-6.2%) and death (0.2%-1.4%). 4, [6] [7] [8] [9] [10] [11] [12] [13] [14] : prematurity (4.95), infants without prematurity (1.61), cardiac surgery during the same admission, prior heart transplantation (2.78), hemodialysis (19.40) Beghetti et al, 2016 diagnoses in those included for analysis were PH associated with congenital heart disease (46%), IPAH (26%), and PH after orthotopic heart transplant (17%).
Catastrophic AEs included death up to 24 hours after catheterization, cardiac arrest, and/or initiation of extracorporeal membrane oxygenation within 30 days. The raw observed risk for catastrophic AEs was 1.4%, and the adjusted risk was 0.9%. The observed risk of death before discharge was 5.2%. This study provides new data showing several patient-level factors that increase risk with PH-HC: premature neonate (odds ratio [OR], 3.98), infant without prematurity (OR, 1.72), and pretreatment with inotropes (OR, 7.23). Higher systemic arterial saturation was protective of catastrophic AEs (OR, 0.81 per D5% saturation) as was higher cardiac index (OR, 0.75 per 1 L/min per m 2 ). The degree of PH was also associated with higher catastrophic AE risk: PVR (OR, 1.08 per 1 WU/m 2 ) and mPA pressure (OR, 1.21 per 10 mm Hg). Center PH-HC volume was also found to reduce risk of catastrophic AEs (OR, 0.84), yet it could not be determined if this was strictly because of increased procedural volume or overall center expertise in the treatment of PH. The main limitations in this study are that subjects had milder PH than in prior studies, data on upstream PH medications were not available (thereby limiting the ability to understand how specific targeted therapy affects risk/ outcome with HC), and sample size limited the ability to report the magnitude of risk that PH severity plays in AEs.
Overall catastrophic AE risk in this study is similar to prior administrative and registry data sets. Important information shown herein is that children with PH have similar HC risk factors for AEs, including premature neonates, term infants, and pretreatment with inotropes. Higher systemic arterial saturation and cardiac index were associated with lower AEs at the time of HC. These new data highlight that sequential increase in PVR or mPA pressure increases catastrophic AEs linearly. Center experience was also shown to affect catastrophic AE risk. Of the risk factors for development AEs in pediatric PH-HC identified in this study, only a few are potentially modifiable: pretreatment with inotropes, higher PVR, higher mPA pressure, and center experience. In the context of prior studies ( Table) , we propose that clinicians identify children with PH who are at higher risk for AEs and consider early expert PH evaluation to determine if up-front pulmonary vasodilator therapy, risk factor modification or avoidance of HC are reasonable to reduce AE risk (Figure) . If possible, avoidance of general anesthesia or concurrent intervention during diagnostic HC are reasonable.
In conclusion, pediatric patients with PH have a higher AE risk when undergoing HC. The current study illustrates that the severity of PH linearly affects risk and that center experience matters. We propose early risk stratification and consideration of expert PH evaluation for those who are high risk, in addition to avoidance of general anesthesia and concurrent HC intervention, if possible. Further research aimed at refining individual risk assessment, including details about prior PH medical therapy, is needed to best risk stratify this population before invasive testing. Figure. Pediatric pulmonary hypertension heart catheterization (PH-HC) risk. This algorithm represents one potential method to evaluate PH-HC risk in children; it is based on the findings in studies outlined in the Table and the current study by O'Byrne and colleagues. 15 *We recommend that the institutional PH expert/ team assess each patient where the decision tree leads to "consideration of pre-HC pulmonary vasodilator therapy." The goal of this team is to determine if pre-HC pulmonary vasodilator therapy is required, and when indicated, to recommend the specific type of therapy on the basis of individual patient characteristics. EDP indicates end diastolic pressure; FC, functional class; GA, gestational age; mPAP, mean pulmonary artery pressure; MV, mixed venous; PASP, pulmonary artery systolic pressure; RVSP, right ventricular systolic pressure; Sat, saturation; SV, single ventricle; TR, tricuspid regurgitation (referring to jet velocity on ECG); and WHO, World Health Organization.
